News by topic

Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Lipodystrophy news

Show

From To
Lipodystrophy
Reductions in visceral fat during tesamorelin therapy associated with improvements in key metabolic markers

Reductions in visceral adiposity achieved with tesamorelin therapy are associated with improvements in some key metabolic parameters, according to a study published in the online edition of

Published
30 April 2012
By
Michael Carter
Side-effects
Why it's time to say goodbye to stavudine...everywhere

Concerns about a proposed comparative trial of 40mg and 20mg (low-dose) stavudine in South Africa.

Published
16 April 2012
From
South African Journal of HIV Medicine
Lipodystrophy
Lipoatrophy common in children receiving d4T in South Africa

Exposure to d4T (stavudine) among young children in sub-Saharan Africa remains the greatest risk factor for lipodystrophy syndrome (that includes lipoatrophy and lipohypertrophy) for a significant proportion of

Published
07 March 2012
By
Carole Leach-Lemens
Neurological and cognitive problems
Fat accumulation linked to cognitive impairment in patients with HIV

Central fat accumulation is associated with an increased risk of neurocognitive impairment for HIV-positive patients, according to a study published in the February edition of Neurology. Overall 40%

Published
24 February 2012
By
Michael Carter
Lipodystrophy
Face fillers and dental work—caution needed

Reconstructive surgery to deal with the loss of subcutaneous fat in the face involved injection of facial fillers. One product used was polyalkylimide gel (PAIG, Bio-Alcamid). However, reports began to emerge from Western Europe of inflammation and infections in both HIV-negative and HIV-positive people with Bio-Alcamid implants. 

Published
25 January 2012
From
CATIE
Pharmaceutical industry
Theratechnologies to discontinue COPD clinical program and focus on lipodystrophy

The Company will now focus its efforts on tesamorelin's significant potential for the treatment of excess abdominal fat in HIV patients with lipodystrophy. Currently, applications for this indication are under review with regulatory agencies in Europe, Argentina, Brazil, Canada, Israel and Mexico.

Published
08 December 2011
From
Theratechnologies press release
Side-effects
Raltegravir kinder to bones and body fat than boosted protease inhibitors in Spanish trial

Raltegravir (Isentress)-based treatment appears to have a more favourable impact on fat accumulation and bone metabolism compared to therapy based on a ritonavir-boosted protease inhibitor, according to Spanish

Published
28 November 2011
By
Michael Carter
Ageing and HIV
Diseases of ageing occurring 10 to 15 years earlier in patients with HIV

The diseases of ageing develop earlier in patients with HIV than in the general population, Italian investigators report in the online edition of Clinical Infectious Diseases. “Our findings

Published
20 October 2011
By
Michael Carter
Cardiovascular disease
Waist circumference and triglycerides: simple measures of increased cardiovascular risk for patients with HIV

Measuring waist circumference and triglyceride levels may be an easy way of identifying which HIV-positive patients have an increased risk of cardiovascular disease, according to research published

Published
10 October 2011
By
Michael Carter
Lipodystrophy
Kivexa and Truvada-based combinations associated with long-term gains in limb fat, not fat loss

Modern antiretroviral regimens based on Kivexa and Truvada are associated with long-term gains in limb fat, US investigators report in the July 15th edition of Clinical Infectious Diseases.

Published
27 June 2011
By
Michael Carter
← First123...4Next →

Filter by country